US IPO Lays Into EU Plans To Cut Data Protection & Extend ‘Bolar’ Exemption
Executive Summary
The IPO says some provisions in the EU pharma revision could contravene the TRIPS agreement, including plans to suspend regulatory data protection on products subject to a compulsory licence in times of health emergencies.